UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 2, 2022
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices and zip code)
(203 ) 208-4111
(Registrant’s telephone number, including area code)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Common Stock, par value $0.001 per share | ||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 2, 2022, Isoplexis Corporation issued a press release reporting its financial results for the quarter and year ended December 31, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No. | Description | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ISOPLEXIS CORPORATION | ||||||||||||||
Date: March 2, 2022 | ||||||||||||||
| By: | /s/ John Strahley | |||||||||||||
| Name: | John Strahley | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
2
 | Exhibit 99.1 | |||||||
IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022
2021 revenue increased 66% over prior year period
BRANFORD, CONN., March 2, 2022 – IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021.
Recent Highlights
•Revenue of $5.5 million for the fourth quarter and $17.3 million for the full year 2021, representing 63% and 66% increases, respectively, over the corresponding periods of 2020
•Sold 98 new instruments in 2021, bringing the installed base to 209 total instruments
•Released The Superhuman Cell Library, an industry-first mapping of the proteomically driven cells that determine how the human body responds to complex disease
•Presented new data generated on the IsoLight highlighting how to leverage “superhero” cells for optimization of CAR-T manufacturing as well as clinical immunotherapies for hematologic malignancies and functional biomarkers of potency, durability, and survival
•Demonstrated commercial traction with 67% of US Comprehensive Cancer Centers and 100% of top 15 pharma companies by revenue now using IsoPlexis platforms for functional cell analysis
•Demonstrated broad applicability of technology beyond the cell therapy and cancer immunology markets through a recent immune monitoring Covid-19 study published in the Cell journal, and released additional applications for the next-gen Duomic platform
“2021 was an exciting year for IsoPlexis as we transitioned to being a public company,” said Sean Mackay, Co-founder and CEO of IsoPlexis. “We made significant progress across multiple fronts with revenue growing 66% year-over-year, instruments placed in all 15 of the top pharma companies and in more than two thirds of Comprehensive Cancer Centers. We look forward to continuing this commercial momentum in 2022 as well as making significant progress on our ambitious product roadmap.”
Fourth Quarter 2021 Financial Results
Revenue was $5.5 million for the three months ended December 31, 2021, a 63% increase from $3.4 million for the three months ended December 31, 2020. These results were primarily driven by an increase in instruments sold.
Gross margin was 51% for the fourth quarter of 2021, as compared to 53% for the corresponding prior year period.
Operating expenses were $27.5 million for the fourth quarter of 2021, a 145% increase from $11.2 million for the three months ended December 31, 2020. The increase in operating expenses was primarily driven by headcount expansion across our business, and the additional costs of being a public company.
Operating loss was $24.6 million for the fourth quarter of 2021, as compared to $9.4 million for the corresponding prior year period.
Net loss was $25.3 million for the fourth quarter of 2021, as compared to a net loss of $8.0 million for the corresponding prior year period.
1
Full Year 2021 Financial Results
Revenue was $17.3 million for the year ended December 31, 2021, a 66% increase from $10.4 million for the year ended December 31, 2020.
Gross margin was 51% for 2021, as compared to 52% for the prior year period.
Operating expenses were $85.1 million for 2021, as compared to $32.7 million for the prior year period, an increase of 160%.
Operating loss was $76.3 million for 2021, as compared to $27.3 million for the corresponding prior year period.
Net loss was $81.6 million for 2021, as compared to a net loss of $23.3 million for the corresponding prior year period.
Cash was $126.6 million as of December 31, 2021.
2022 Guidance
IsoPlexis expects full year 2022 revenue to be in the range of $26 million to $27 million, representing 51% to 56% growth over full year 2021.
Webcast Information
IsoPlexis will host a conference call to discuss the fourth quarter 2021 financial results before market open on Wednesday, March 2, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at http://investors.isoplexis.com. The webcast will be archived and available for replay for at least 90 days after the event.
Please also find our updated investor presentation on our website (https://investors.isoplexis.com/news-events/presentations).
About IsoPlexis
IsoPlexis is the Superhuman Cell company.
IsoPlexis’ systems uniquely identify a comprehensive range of multifunctional single cells, i.e. the superhero cells in the human body. These cells enable researchers to understand and predict disease progression, treatment resistance and therapeutic efficacy to advance all of human health.
IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at two-thirds of leading U.S. comprehensive cancer centers.
Forward Looking Statements
This press release contains “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies and other future conditions. Such forward-looking statements may include, without limitation, statements about future opportunities for us and our products and services, our future operations, financial or operating results, including our financial guidance, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions and other expectations and targets for future periods. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “target,” “potential,” “seek,” “will,” “would,” “could,” “continuing,” “forward,” “should,” “continue,” “contemplate,” “plan,” and other words and terms of similar meaning. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that
2
actual performance and outcomes may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if our results of operations, financial condition and cash flows, and the development of the markets in which we operate, are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to predict all of them.
Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, among others, the following: estimates of our addressable market, market growth, future revenue, expenses, capital requirements and our needs for additional financing; the implementation of our business model and strategic plans for our products and technologies; competitive companies and technologies and our industry; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to develop and commercialize new products; our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement; the performance of third party suppliers; our ability to hire and retain key personnel and to manage our future growth effectively; our ability to obtain additional financing in future offerings; the volatility of the trading price of our common stock; our expectations regarding use of proceeds from our initial public offering (“IPO”); the potential effects of government regulation; the impact of COVID-19 on our business; and our expectations about market trends. For a further discussion of these and other factors that could impact our future results, performance or transactions, see the section “Risk Factors” included in our Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 12, 2021, and our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. We qualify all of the forward-looking statements in this press release by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
3
IsoPlexis Corporation and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
Year ended December 31, | ||||||||||||||
| (in thousands, except share and per share amounts) | 2021 | 2020 | ||||||||||||
| Revenue | ||||||||||||||
| Product revenue | $ | 16,201 | $ | 9,318 | ||||||||||
| Service revenue | 1,057 | 1,069 | ||||||||||||
| Total revenue | 17,258 | 10,387 | ||||||||||||
| Cost of product revenue | 8,445 | 4,866 | ||||||||||||
| Cost of service revenue | 47 | 108 | ||||||||||||
| Gross profit | 8,766 | 5,413 | ||||||||||||
| Operating expenses: | ||||||||||||||
| Research and development expenses | 20,966 | 11,157 | ||||||||||||
| General and administrative expenses | 26,349 | 8,023 | ||||||||||||
| Sales and marketing expenses | 37,774 | 13,511 | ||||||||||||
| Total operating expenses | 85,089 | 32,691 | ||||||||||||
| Loss from operations | (76,323) | (27,278) | ||||||||||||
| Other income (expense): | ||||||||||||||
| Interest (expense), net | (3,618) | (18) | ||||||||||||
| Other (expense) income, net | (1,628) | 4,032 | ||||||||||||
| Net loss | $ | (81,569) | $ | (23,264) | ||||||||||
| Accrued dividends on preferred stock | (10,455) | (6,137) | ||||||||||||
| Net loss attributable to common stockholders | $ | (92,024) | $ | (29,401) | ||||||||||
| Basic and diluted net loss per common share | $ | (8.99) | $ | (14.06) | ||||||||||
| Weighted-average common shares outstanding—basic and diluted | 10,239,869 | 2,090,392 | ||||||||||||
4
IsoPlexis Corporation and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
| December 31, | ||||||||||||||
| (in thousands, except share amounts) | 2021 | 2020 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash | $ | 126,566 | $ | 106,641 | ||||||||||
| Accounts receivable, net | 4,100 | 2,922 | ||||||||||||
| Inventories, net | 24,299 | 3,955 | ||||||||||||
| Prepaid expenses and other current assets | 3,478 | 2,156 | ||||||||||||
| Total current assets | 158,443 | 115,674 | ||||||||||||
| Property and equipment, net | 5,778 | 3,227 | ||||||||||||
| Intangible assets, net | 21,008 | 1,643 | ||||||||||||
| Other assets | 2,243 | 3,061 | ||||||||||||
| Total assets | $ | 187,472 | $ | 123,605 | ||||||||||
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 4,839 | $ | 2,137 | ||||||||||
| Accrued expenses and other current liabilities | 7,827 | 2,129 | ||||||||||||
| Deferred revenue | 915 | 356 | ||||||||||||
| Total current liabilities | 13,581 | 4,622 | ||||||||||||
| Warrant liability | — | 4,637 | ||||||||||||
| Long-term debt | 31,646 | 22,137 | ||||||||||||
| Total liabilities: | 45,227 | 31,396 | ||||||||||||
| Commitments and Contingencies | ||||||||||||||
| Redeemable convertible preferred stock, $0.001 par value, zero and 3,442,340 shares authorized at December 31, 2021 and 2020, respectively; zero and 3,211,652 shares issued and outstanding at December 31, 2021 and 2020, respectively | — | 143,460 | ||||||||||||
| Stockholders’ deficit: | ||||||||||||||
| Preferred stock, $0.001 par value; 20,000,000 and zero shares authorized at December 31, 2021 and 2020, respectively; and zero shares issued or outstanding | — | — | ||||||||||||
Common stock, $0.001 par value, 400,000,000 shares authorized; 39,036,010 and 2,133,904 shares issued and outstanding as of December 31, 2021 and 2020, respectively | 39 | 2 | ||||||||||||
| Additional paid-in capital | 276,179 | 1,151 | ||||||||||||
| Accumulated deficit | (133,973) | (52,404) | ||||||||||||
| Total stockholders’ equity (deficit) | 142,245 | (51,251) | ||||||||||||
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $ | 187,472 | $ | 123,605 | ||||||||||
5